Document:

ex10_2.htm

[Pursuant to 17 C.F.R. 240.24b-2, confidential information has been omitted in places marked “[...***...]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application.]

  

  

RESEARCH AGREEMENT

  

(“Agreement”)

  

  

Pfizer Inc, a Delaware corporation with an address at 235 East 42nd Street, New York, New York 10017 (“PFIZER”), and BioRestorative Therapies, Inc., a Nevada corporation with an address at 555 Heritage Drive, Jupiter, Florida 33458 (“BRT”), enter into this Agreement for the conduct of studies entitled “Development and Validation of a Human Brown Adipose Cell Model” as set forth in the research plan attached as Exhibit A (“Research Plan”).

  

	
1. 

	
DEFINITION:

  

	
1.1. 

	
“Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls, is controlled by, or is under common control with a particular party.

	
1.2. 

	
“Applicable Law” means any statute, law, treaty, rule, code, ordinance, regulation, permit, interpretation, certificate or order of a Governmental Authority, or any judgment, decision, decree, injunction, writ, order, subpoena, or like action of any court, arbitrator or other government entity related to the collection, retention, security and use of the Material, as the same are promulgated and applied as of the effective date of this Agreement and at all times thereafter.

	
1.3. 

	
“BRT Material” means all materials or samples (including, without limitation, [...***...]) provided by or on behalf of or otherwise made available by or on behalf of BRT to PFIZER pursuant to or otherwise in connection with this Agreement.

	
1.4. 

	
“BRT Results” means and includes all technology, materials, intellectual property and technical information that are developed by BRT employees, technicians or others working solely on behalf of BRT (excluding any PFIZER employees or contractors) in performance of the Research Plan.

	
1.5. 

	
“Donor” means the donor of the Donor Material or of the original tissues from which the Donor Material was derived.

	
1.6. 

	
“Donor Material” means cells, cell cultures, blood, fluids, tissues, genetic information (including data or results derived from human brown and white adipose cell lines).

	
1.7. 

	
“Governmental Authority” means any federal, state, local or foreign government entity, authority, agency, instrumentality, court, tribunal, regulatory commission or other body, whether legislative, judicial, administrative or executive (or a combination or permutation thereof), and any arbitrator to whom a dispute has been presented under government rule or by agreement of the parties with an interest in such dispute.

	
1.8. 

	
“HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as codified at 42 USC § 1320(d) and all regulations promulgated thereunder.

  

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

  

  

	
1.9. 

	
“Patient Identifiable Information” means any information (whether or not key coded) that identifies, or could identify, the Donor and/or any individually identifiable, or potentially individually identifiable, health information of that Donor, including, without limitation, Protected Health Information (as defined in 45 CFR § 164.501) or Individually Identifiable Health Information (as defined in 42 USC § 1320(d)) and other information protected by data protection and/or privacy legislation in any and all applicable territories.

	
1.10. 

	
"PFIZER Material" means all materials or samples (including, without limitation, [...***...]) provided by or on behalf of or otherwise made available by or on behalf of PFIZER to BRT pursuant to or otherwise in connection with this Agreement.

	
1.11. 

	
“PFIZER Results” means and includes all technology, materials, intellectual property and technical information that are developed by PFIZER employees, technicians or others working solely on behalf of PFIZER (excluding any BRT employees or contractors) in performance of the Research Plan.

	
1.12. 

	
“Privacy Board” means a review body that is established to act upon requests for a waiver or an alteration of the authorization requirement under the privacy rule for uses and disclosures of Patient Identifiable Information for the relevant research study.

  

	
2. 

	
SCOPE OF WORK: BRT, under the direction of principal investigator, Francisco Silva, Vice President, Research & Development (“Principal Investigator”), will perform the studies and provide to PFIZER the data and reports described in the Research Plan.

  

	
3. 

	
TERM: The term of this Agreement is effective as of March 24th, 2014 (“Effective Date”) and unless earlier terminated or extended, continues for two (2) years until March 23rd ,2016 (the “Expiration Date”), or until the completion of the work described in the Research Plan, whichever comes first.

  

	
4. 

	
PAYMENT: PFIZER will pay BRT up to the sum of $775,000 (Seven Hundred and Seventy Five Thousand Dollars) during the term of this Agreement according to the following payment schedule:

	
· 

	
The sum of $250,000 (Two Hundred Fifty Thousand Dollars) (the “Initial Payment”) – which represents technology access fee, upfront costs, and Q1 labor costs associated with Workstream #1 -- will be payable concurrently with the execution of this Agreement.

	
· 

	
The sum of $356,250 (Three Hundred Fifty-Six Thousand Two Hundred Fifty Dollars) (the “Second Installment”) will be payable in four (4) equal quarterly installments (of $89,062.50 for Q2, Q3, Q4, and Q5) commencing on the three (3) month anniversary of the Effective Date and continuing every three (3) months thereafter (each, a “Quarterly Period”); provided, however, that, in the event of the achievement of Workstream #1 Deliverable #1 -- Delivery from BRT to PFE of [...***...], the balance of the Second Installment shall be due and payable.

	
· 

	
The sum of $168,750 (One Hundred Sixty-Eight Thousand Seven Hundred Fifty Dollars) (the “Third Installment”) will be payable in two (2) equal bi-annual installments (of $84,375) following the Second Installment and continuing every six (6) months thereafter (each, a “Bi-Annual Period”); provided, however, that, in the event of achievement of Workstream #2 Deliverable #2 -- analysis of [...***...] and delivery of the final report to PFIZER, the balance of the Third Installment shall be due and payable.

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

	
  

	
Payments under this Agreement will be due within thirty (30) days following PFIZER’s receipt of an invoice from BRT (except that the Initial Payment shall be paid concurrently with the execution of this Agreement).

  

All invoices shall be delivered to PFIZER c/o: PFIZER INC. GFSS – AMERICAS, PO Box 34600, Bartlett, TN 38184-0600, United States. To receive payment from your purchase order (PO), mail a document clearly marked 'INVOICE' to the address above (or email apinvoices@pfizer.com) with the following information clearly listed: Description of research conducted, and/or goods provided, PO number, amount owed and name and address payment is to be sent to. This will help facilitate a quick payment to BRT for research conducted. BRTs enrolled in PFIZER's e-Invoicing programs (ASN or OB10) can ignore this PO Note. All invoice or billing related questions should be referred to PFIZER's Accounting Department at 800.601.1357 or go to the Accounts Payable Inquiry Tool (APIQ) at www.pfizeraccountspayable.com.

  

In addition, a copy of each invoice will be mailed and emailed to:

  

Michael Rukstalis, Principal Scientist

  

CVMED Research Unit

  

Pfizer Worldwide Research & Development

  

Cambridge Laboratories

  

610 Main St

  

Cambridge, MA 02139

  

 

  

with an electronic copy to:

  

Michael Rukstalis at: michael.rukstalis@pfizer.com

  

  

	
5. 

	
PFIZER & BRT MATERIAL:

	
5.1.1. 

	
Ownership, Delivery and Handling. BRT acknowledges and agrees that, as between the parties, PFIZER is and shall at all times remain the sole and exclusive owner of the PFIZER Material and all intellectual property rights therein. PFIZER acknowledges and agrees that, as between the parties, BRT is and shall at all times remain the sole and exclusive owner of the BRT Material and all intellectual property rights therein. PFIZER will supply BRT with such quantities and types of the PFIZER Material as PFIZER in its sole discretion determines is appropriate under the Research Plan, and BRT will supply PFIZER with such quantities and types of the BRT Material as BRT in its sole discretion determines is appropriate under the Research Plan. Upon the sooner of the expiration or termination of this Agreement or upon the request of PFIZER, BRT shall, in accordance with PFIZER’s instructions, return to PFIZER, or destroy at PFIZER’s option with written certification of such destruction sent to PFIZER, all unused PFIZER Material. Upon the sooner of the expiration or termination of this Agreement or upon the request of BRT, PFIZER shall, in accordance with BRT’ instructions, destroy with written certification of such destruction sent to BRT, all stem cell lines in PFIZER’s possession that were developed by BRT during the performance of the Research Plan and were not selected by PFIZER pursuant to the Workstream 1 Deliverables set forth in the Research Plan for further analysis in Workstream 2.

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

	
5.1.2. 

	
Experimental Materials. BRT acknowledges that the PFIZER Material comprises experimental materials and BRT will comply with all laws and regulations applicable to handling and use of such materials. BRT will not use the PFIZER Material for testing in or treatment of human subjects. PFIZER acknowledges that the BRT Material comprises experimental materials and PFIZER will comply with all laws and regulations applicable to handling and use of such materials. PFIZER will not use the BRT Material for testing in or treatment of human subjects.

  

	
5.1.3. 

	
NO WARRANTY. THE PFIZER MATERIAL AND BRT MATERIAL ARE PROVIDED TO THE OTHER PARTY AS-IS AND WITHOUT WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, TITLE, OR FITNESS FOR A PARTICULAR PURPOSE.

  

	
5.1.4. 

	
Transfer of Material. BRT will not transfer, disclose, make available, or sell any of the PFIZER Material to any third party. BRT shall not modify or use the PFIZER Material other than as expressly permitted under the Research Plan. PFIZER will not transfer, disclose, make available, or sell any of the BRT Material to any third party except as permitted under Section 6(a).

  

	
5.1.5. 

	
Use of Material. BRT will use the PFIZER Material solely for the purpose of performing the Research Plan. BRT shall not analyze the PFIZER Material or attempt in any way to discover the identity, structure, mechanism of action, or composition of the PFIZER Material other than as expressly permitted under the Research Plan. Notwithstanding any provision in this Agreement to the contrary, PFIZER shall not be obligated at any time to disclose to BRT the identity, structure, composition of, or other information concerning, the PFIZER Material.

	
6. 

	
INTELLECTUAL PROPERTY:

(a) BRT Materials; BRT Results. [...***...]

 

(b) PFIZER Related IP. [...***...]

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

(c) PFIZER Materials; PFIZER Results. [...***...]

 

(d) [...***...]

	
7. 

	
INFORMATION: For purposes of this Agreement, the term “Information” means all written information relating to the studies described in the Research Plan, including but not limited to data, know-how, materials, compound samples and compound specifications which PFIZER shall deliver to BRT, or BRT shall deliver to PFIZER, pursuant to this Agreement, stamped “Confidential,” or disclosed to BRT or PFIZER, as the case may be, orally declaring same to be confidential and confirming such declaration in writing within thirty (30) days of disclosure.

	
8. 

	
CONFIDENTIALITY: Each party agrees to maintain the Information in confidence with the same degree of care it holds its own confidential information. Neither party will use the Information except for the studies described in the Research Plan or as otherwise permitted herein to practice the rights granted herein. Each party will disclose the Information only to its officers, directors, employees and consultants directly concerned with the studies, but will neither disclose information to any third party nor use the Information for any other purpose.

	
9. 

	
EXCEPTIONS TO CONFIDENTIALITY: Each party’s obligation of nondisclosure and the limitations upon the right to use the Information shall not apply to the extent that such party can demonstrate that the Information: (a) was in the possession of such party prior to the time of disclosure; or (b) is or becomes public knowledge through no fault or omission of such party; or (c) is obtained by such party from a third party under no obligation of confidentiality to the other party.

	
  

	
In the event a party is legally required to disclose any of the Information, such party shall provide prompt prior written notice of such requirement to the other party, afford the other party an opportunity to secure confidential treatment for such disclosure, and if the other party is unsuccessful, furnish only that portion of the Information which such party is legally required to disclose.

  

	
10. 

	
SURVIVAL OF CONFIDENTIALITY OBLIGATIONS: All obligations relating to confidentiality of the parties under this Agreement shall survive the termination of this Agreement for a period of [...***...].

	
11. 

	
DONOR MATERIAL: BRT represents that the Donor Material used in, provided to PFIZER, pursuant to this Agreement will conform to the overall description, features, function and specifications set forth in the Research Plan. Furthermore, BRT represents and warrants the following:

	
11.1. 

	
BRT will not provide to PFIZER any medical information or Patient Identifiable Information about any Donor.

	
11.2. 

	
BRT will comply with all Applicable Laws and obtain all required governmental permits, licenses and authorizations in the collection and handling of the Donor Material.

	
11.3. 

	
Collection of the Donor Material has been approved by an Institutional Review Board (“IRB”) that complies with all Applicable Laws for such a body.

	
11.4. 

	
An IRB-approved informed consent form (“ICF”) compliant with all Applicable Laws, will be signed by and obtained from each Donor (or Donor’s representative in the event that the Donor is incapacitated) prior to donation in respect of each Donor Material (or the tissue from which the Material was derived) (“Informed Consent”).

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

  

  

	
11.5. 

	
BRT has legal right and title to the Donor Material and has the required Donor consent to transfer the Donor Material to PFIZER.

	
11.6. 

	
Uses of the Donor Material described in the Research Plan are within the scope of and consistent with BRT’s ethical approval policies, if any, the Informed Consent, and the IRB’s approval.

	
12. 

	
REPORTS: BRT shall cause the Principal Investigator to furnish to PFIZER a comprehensive report within thirty (30) days of the one year anniversary of the Effective Date, describing in reasonable detail the work accomplished on the studies described in the Research Plan.

	
13. 

	
DISCLOSURE OF FEES: As part of any disclosure policy that may be implemented from time-to-time by a party regarding payments made to members of the medical or scientific community, or in accordance with applicable laws or regulations, such party shall have the right to disclose any terms related to this Agreement, including the Principal Investigator’s name and the fees provided to BRT hereunder.

	
14. 

	
HANDLING OF PATIENT INFORMATION:

	
14.1. 

	
BRT and PFIZER will each comply in all material respects with all Applicable Law regarding the privacy of Patient Identifiable Information (including during collection, use, storage, and disclosure), including, but not limited to, HIPAA and any current and future regulations promulgated thereunder including without limitation the federal privacy regulations contained in 45 CFR Parts 160 and 164, the federal security standards contained in 45 CFR Parts 106 and 162, all collectively referred to herein as “HIPAA Requirements”).

	
14.2. 

	
BRT agrees to collect, use, store, and disclose Patient Identifiable Information collected or provided as part of the Research Plan and for the purpose of complying with applicable law, provided that all such uses are disclosed in the ICF.

	
14.3. 

	
BRT will ensure that that ICF provides PFIZER may use the Donor Material for any research, development and regulatory purpose.

	
14.4. 

	
BRT agrees that it will not disclose to PFIZER any Patient Identifiable Information of any Donor and PFIZER will not attempt to identify any Donor.

	
14.5. 

	
If PFIZER inadvertently receives Patient Identifiable Information from BRT, PFIZER will take appropriate measures to protect the privacy and confidentiality of such information and to ensure that PFIZER’s collaborators take similar measures.

	
15. 

	
ENTIRE AGREEMENT: This Agreement sets forth the entire agreement between PFIZER and BRT as to its subject matter. None of the terms of this Agreement shall be amended except in writing signed by both parties.

  

	
16. 

	
BREACH AND TERMINATION: If either party breaches this Agreement in any material respect, the other party may terminate it if the breaching party does not cure the breach within thirty (30) days of written notice of the same (a “Breach Termination”). PFIZER may terminate this Agreement with or without cause by giving thirty (30) days notice to BRT in writing. If PFIZER terminates this Agreement based upon a Breach Termination, then PFIZER’s obligation to make payments that are due after the termination date shall cease; provided, however, that, in the event that PFIZER terminates this Agreement other than pursuant to a Breach Termination, then, in addition to the Initial Payment and any Second Installment payments already due, BRT shall be entitled to receive all quarterly Second Installment payments that are due through the end of the Quarterly Period in which the termination date falls and, if the notice of termination is sent following the commencement of any Workstream 2 work, BRT shall be entitled to receive all bi-annual Third Installment payments that are due through the end of the Bi-Annual Period in which the termination date falls. The right of termination shall be an addition to any other rights the terminating party may have, at law or equity, pursuant to this Agreement. Sections 1, 5, 6, 8, 9, 10, 15 and 18 shall survive any termination of this Agreement, whether due to a breach or otherwise.

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

  

	
17. 

	
COMPLIANCE WITH LAWS: Both PFIZER and BRT shall comply in all material respects with the requirements of all Applicable Laws, rules, regulations and orders of any government authority including laws related to animal welfare. BRT will comply with Pfizer’s animal care and use policy -- http://www.pfizer.com/research/research_clinical_trials/laboratory_animal_care . BRT will procure all Donor Material in accordance with all Applicable Laws. Additionally, PFIZER agrees to use the Donor Material in compliance with all Applicable Laws. BRT shall not use services of any BRT employees that have been or are currently debarred or otherwise disqualified by the United States Food and Drug Administration or other regulatory or certification authority.

	
17.1. 

	
Regulatory. BRT is solely responsible for any and all safety reporting and regulatory obligations associated with the procurement of the Donor Material.

	
17.2. 

	
Standards. BRT will procure the Donor Material in accordance with International Conference on Harmonization Good Clinical Practice (“ICH GCP”) guidelines (to the extent applicable), and all Applicable Laws. BRT will comply with all IRB requirements relating to the procurement of Donor Materials.

	
17.3. 

	
IRB Approval. If required, BRT will ensure that the procurement of the Donor Material is approved by and subject to continuing oversight by an appropriate IRB.

	
17.4. 

	
Informed Consent. As required, BRT will obtain Informed Consent from each Donor in accordance with Applicable Law (including without limitation 21 Code of Federal Regulations Part 50), ensure that Informed Consent that covers the research to be conducted has already been obtained, or obtain a waiver of Informed Consent for procurement of the Donor Material from an appropriate IRB. If an Informed Consent is used, BRT will inform Donors that Pfizer is providing support for procurement of the Donor Material. Pfizer has no obligation to participate in the development of, or to review or comment on, an ICF, authorization, or waiver request.

  

	
18. 

	
CHOICE OF LAW: This Agreement shall be construed in accordance with the laws of the State of New York, excluding choice of law principles thereof.

  

[Remainder of page intentionally left blank. Signature page follows.]

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

  

IN WITNESS WHEREOF, duly-authorized representatives of the parties have signed as of the dates written below.

  

	
BioRestorative Therapies, Inc.

	 	
Pfizer Inc.

	 	 	 
	
By: 

	 	
By: 

	 	 	 
	
Print Name: 

	 	
Print Name: 

	 	 	 
	
Title: 

	 	
Title: 

	
(Duly authorized)

	 	
(Duly authorized)

  

  

 

[...***...] Confidential information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information.

 

 

EXHIBIT A

  

RESEARCH PLAN

  

[...***...]

  

  

[...***...]  Confidential information has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to this omitted information.  A total of eight pages have been redacted from Exhibit A.EXHIBIT 10.32

 

SECURITIES PURCHASE AGREEMENT, DATED JUNE
23, 2014 BETWEEN THE COMPANY AND PEAK ONE

 

 

SECURITIES
PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (the “Agreement”), dated as of June 23, 2014, is entered into by and between Surepure,
Inc., a Nevada corporation, (the “Company”), having its address at 405 Lexington Avenue, 25th Floor,
New York, NY 10174, and Peak One Opportunity Fund, L.P., a Delaware limited partnership
(the “Buyer”), having its address at 333 South Hibiscus Drive, Miami Beach, FL 33139.

 

WITNESSETH:

 

WHEREAS, the
Company and the Buyer are executing and delivering this Agreement in accordance with and in reliance upon the exemption from securities
registration afforded, inter alia, by Rule 506 under Regulation D (“Regulation D”) as promulgated by the United
States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933
Act”), and/or Section 4(2) of the 1933 Act; and

 

WHEREAS, the
Buyer wishes to purchase from the Company, and the Company wishes to sell the Buyer, upon the terms and subject to the conditions
of this Agreement, securities consisting of the Company’s Convertible Debentures due three years from the respective dates
of issuance (the “Debentures”), each of which are in the form of Exhibit A hereto, which will be convertible
into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate
principal amount of up to Three Hundred Seventy-Five Thousand and 00/100 Dollars ($375,000), for an aggregate purchase price of
up to Three Hundred Thirty-Seven Thousand Five Hundred and 00/100 Dollars ($337,500.00), all upon the terms and subject to the
conditions of this Agreement, the Debentures, and other related documents;

 

NOW THEREFORE,
in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.     
DEFINITIONS; AGREEMENT TO PURCHASE.

 

a.      
Certain Definitions. As used herein, each of the following terms has the meaning set forth below, unless the context otherwise
requires:

 

(i)                
“Affiliate” means, with respect to a specific Person referred to in the relevant provision, another Person who or which
controls or is controlled by or is under common control with such specified Person.

 

    	 

    	 

    

  

(ii)              
“Certificates” means the relevant Restricted Stock certificates duly executed on behalf of the Company and issued hereunder.

 

(iii)            
“Closing Date” means the date on which one of the three Closings are held, which are the Signing Closing Date, the
Second Closing Date and the Third Closing Date.

 

(iv)            
“Common Stock” shall have the meaning ascribed to such term in the Recitals.

 

(v)              
“Conversion Price” means sixty five percent (65%) of the lowest closing bid price (as reported by Bloomberg LP) of
Common Stock for the twenty (20) trading days immediately preceding the date of conversion of the Debentures (subject to equitable
adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events). “Conversion Shares”
means the shares of Common Stock issuable upon conversion of the Debentures.

 

(vi)            
“Dollars” or “$” means United States Dollars.

 

(vii)          
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(viii)        
“Guarantee Agreement” shall have the meaning ascribed to such term in Section 3(d).

 

(ix)            
“Material Adverse Effect” means a material adverse effect on the business, operations or condition (financial or otherwise),
prospects or results of operation of the Company and its Subsidiaries taken as a whole, in the sole and absolute discretion of
the Buyer, irrespective of any finding of fault, magnitude of liability (or lack of financial liability) or purported lack of materiality
(it being understood that the mere finding of any such violation is in itself material and adverse). Without limiting the generality
of the foregoing, the occurrence of any of the following, in the sole an absolute discretion of the Buyer, shall be considered
a Material Adverse Effect: (i) the threat or commencement of material litigation in which the Company or any Subsidiary is, or
the Buyer has reason to believe it will be, named as a defendant (including in any event products liability claims against the
Company or its Subsidiaries), (ii) the suspension or withdrawal of any governmental authority or permit pertaining to a material
amount of the Company’s or any Subsidiary’s products or services, (iii) the loss of any material insurance coverage
(including, in any case, comprehensive general liability coverage, products liability coverage or directors and officers coverage,
in each case an in effect at the time of execution and delivery of this Agreement), (iv) the taking of any adverse action by any
Person affecting the Common Stock (including, without limitation, (1) the commencement of any regulatory investigation of which
the Company is aware, the suspension of trading of the Common Stock by the Financial Industry Regulation Authority (“FINRA”),
the SEC, the OTC Bulletin Board (“OTCBB”) or the OTC Markets Group, Inc., the failure of the Common Stock to be DTC
eligible or the placing of the Common Stock on the DTC “chill list” or (2) the engaging in any market manipulation
or other unlawful or improper trading or other activity by any Affiliate), (v) the Company’s independent registered accounts
shall resign under circumstances where a disagreement exists between the Company, (vi) the Company shall fail to timely file any
disclosure document as required by applicable federal or state securities laws and regulations or by the rules and regulations
of any exchange, trading market or quotation system to which the Company or the Common Stock is subject, or (vii) the Chief Executive
Officer of the Company, the Chief Financial Officer of the Company or any other key director of the Company, shall, for any reason
(including, without limitation, termination, resignation, retirement, death or disability) cease to act on behalf of the Company
in the same role and to the same extent as his or her involvement as of the date of execution and delivery of this Agreement.

 

    	2

    	 

    

  

(x)              
“Person” means any living person or any entity, such as, but not necessarily limited to, a corporation, partnership
or trust.

 

(xi)            
“Purchase Price” means the price that the Buyer pays for the Debentures at each respective Closing, which are the Signing
Purchase Price, the Second Purchase Price and the Third Purchase Price, as such are defined in Sections 6(a), 6(b) and 6(c), respectively.

 

(xii)          
“Registration Rights Agreement” shall have the meaning ascribed to such term in Section 3(d).

 

(xiii)        
“Restricted Stock” shall mean shares of Common Stock which are not freely trading shares.

 

(xiv)        
“Securities” means the Debentures and the Shares.

 

 

(xv)          
“Shares” means the Conversion Shares.

 

(xvi)        
“Second Closing Date” shall have the meaning ascribed to such term in Section 6(b).

 

(xvii)      
“Second Debenture” means the second of the three (3) Debentures, in the principal amount of $125,000, which is issued
by the Company to the Buyer at the Second Closing Date.

 

(xviii)    
“Signing Closing Date” shall have the meaning ascribed to such term in Section 6(a).

 

(xix)        
“Signing Debenture” means the first of the three Debentures, in the principal amount of $125,000, to be issued on the
Signing Closing Date.

 

(xx)          
“Subsidiary” shall have the meaning ascribed to such term in Section 3(b).

 

(xxi)        
“Third Closing Date” shall have the meaning ascribed to such term in Section 6(b).

 

(xxii)      
“Third Debenture” means the third of the three (3) Debentures, in the principal amount of $125,000, which is issued
by the Company to the Buyer at the Third Closing Date.

 

(xxiii)    
“Transaction Documents” means, collectively, this Agreement, the Debentures, the Registration Rights Agreement, the
Transfer Agent Instruction Letter, the Guarantee Agreement, and the other agreements, documents and instruments contemplated hereby
or thereby.

 

    	3

    	 

    

  

(xxiv)    
“Transfer Agent” shall have the meaning ascribed to such term in Section 4(a).

 

(xxv)      
“Transfer Agent Instruction Letter” shall have the meaning ascribed to such term in Section 5(a).

 

b.     
Purchase and Sale of Debentures.

 

(i)                
The Buyer agrees to Purchase from the Company, and the Company agrees to sell to the Buyer, the Debentures on the terms and conditions
set forth below in this Agreement and the other Transaction Documents.

 

(ii)              
Subject to the terms and conditions of this Agreement and the other Transaction Documents, the Buyer will purchase the Debentures
at certain closings (each, a “Closing”) to be held on certain respective Closing Dates.

 

2.      BUYER’S
REPRESENTATIONS, WARRANTIES, ETC.

 

The Buyer represents
and warrants to, and covenants and agrees with, the Company as follows:

 

a.      
Investment Purpose. Without limiting the Buyer’s right to sell the Shares pursuant to the Registration Statement,
the Buyer is purchasing the Debentures, and will be acquiring the Conversion Shares, for its own account for investment only and
not with a view towards the public sale or distribution thereof and not with a view to or for sale in connection with any distribution
thereof.

 

b.     
Accredited Investor Status. Buyer is (i) an “accredited investor” as that term is defined in Rule 501 of the
General Rules and Regulations under the 1933 Act by reason of Rule 501(a)(3), (ii) experienced in making investments of the kind
described in this Agreement and the related documents, (iii) able, by reason of the business and financial experience of its officers
(if an entity) and professional advisors (who are not affiliated with or compensated in any way by the Company or any of its affiliates
or selling agents), to protect its own interests in connection with the transactions described in this Agreement, and the related
documents, and (iv) able to afford the entire loss of its investment in the Securities.

 

c.      
Subsequent Offers and Sales. All subsequent offers and sales of the Securities by the Buyer shall be made pursuant to registration
of the Shares under the 1933 Act or pursuant to an exemption from registration and compliance with applicable states’ securities
laws.

 

    	4

    	 

    

  

d.     
Reliance on Exemptions. Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the
Buyer to acquire the Securities.

 

e.      
Information. Buyer and its advisors have been furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer. Buyer and
its advisors have been afforded the opportunity to ask questions of the Company and have received complete and satisfactory answers
to any such inquiries. Without limiting the generality of the foregoing, Buyer has also had the opportunity to obtain and to review
(1) the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2014, and (2) the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (collectively, the “SEC Documents”).

 

f.      
Investment Risk. Buyer understands that its investment in the Securities involves a high degree of risk, including the risk
of loss of the Buyer’s entire investment.

 

g.     
Governmental Review. Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities.

 

h.     
Organization; Authorization. Buyer is duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization. This Agreement and the other Transaction Documents have been duly and validly authorized, executed and delivered
on behalf of the Buyer and create a valid and binding agreement of the Buyer enforceable in accordance with its terms, subject
as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium and other similar laws affecting
the enforcement of creditors’ rights generally.

 

i.       
Residency. The state in which any offer to purchase shares hereunder was made to or accepted by Buyer is the state shown
as the Buyer’s address contained herein.

 

3.      COMPANY
REPRESENTATIONS AND WARRANTIES, ETC. 

 

The Company represents
and warrants to the Buyer that:

 

a.      
Concerning the Debentures and the Shares. There are no preemptive rights of any stockholder of the Company to acquire the
Debentures or the Shares.

 

    	5

    	 

    

  

b.     
Organization; Subsidiaries; Reporting Company Status. Attached hereto as Schedule 3(b) is an organizational chart
describing the Company’s majority-owned subsidiaries (the “Subsidiaries”) and the relationships among the Company
and such Subsidiaries, including as to each Subsidiary its jurisdiction of organization and the percentage of ownership held by
the Company, and the parent company of the Company, including the percentage of ownership of the Company held by it. The Company
and each Subsidiary is a corporation or other form of businesses entity duly organized, validly existing and in good standing under
the laws its respective jurisdiction of organization, and each of them has the requisite corporate or other power to own its properties
and to carry on its business as now being conducted. The Company and each Subsidiary is duly qualified as a foreign corporation
or other entity to do business and is in good standing in each jurisdiction where the nature of the business conducted or property
owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have
a Material Adverse Effect. The Common Stock is listed and traded on the OTCQB Market of the OTC Markets Group, Inc. (trading symbol:
SURP). The Company has received no notice, either oral or written, from FINRA, the SEC, or any other organization, with respect
to the continued eligibility of the Common Stock for such listing, and the Company has maintained all requirements for the continuation
of such listing.

 

c.      
Authorized Shares. Schedule 3(c) sets forth all capital stock and derivative securities of the Company that are authorized
for issuance and that are issued and outstanding. All issued and outstanding shares of Common Stock have been duly authorized and
validly issued and are fully paid and nonassessable. The Company has sufficient authorized and unissued shares of Common Stock
as may be necessary to effect the issuance of the Shares, assuming the prior issuance and exercise, exchange or conversion, as
the case may be, of all derivative securities authorized, as indicated in Schedule 3(c). The Shares have been duly authorized
and, when issued upon conversion of, or as interest on, the Debentures, the Shares will be duly and validly issued, fully paid
and non-assessable and will not subject the holder thereof to personal liability by reason of being such holder. At all times,
the Company shall keep available and reserved for issuance to the holders of the Debentures Common Stock duly authorized for issuance
against the Debentures.

 

d.     
Authorization. This Agreement, the Registration Rights Agreement, dated as of the date hereof, between the Company and the
Buyer, substantially in the form of Exhibit B annexed hereto (the “Registration Rights Agreement”), the Guarantee
Agreement, dated as of the date hereof, between each Subsidiary of the Company and the Buyer, substantially in the form of Exhibit
C annexed hereto (the “Guarantee Agreement”) and the issuance of the Debentures (including without limitation the
incurrence of indebtedness thereunder) and Restricted Stock and the other transactions contemplated by the Transaction Documents,
have been duly and validly authorized by the Company, and this Agreement has been duly executed and delivered by the Company. Each
of the Transaction Documents, when executed and delivered by the Company, are and will be, valid, legal and binding agreements
of the Company, enforceable in accordance with their respective terms, subject as to enforceability to general principles of equity
and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights generally.

 

    	6

    	 

    

  

e.      
Non-contravention. The execution and delivery of the Transaction Documents, the issuance of the Securities and the consummation
by the Company of the other transactions contemplated by this Agreement, the Registration Rights Agreement and the Debentures (including
without limitation the incurrence of indebtedness thereunder) do not and will not conflict with or result in a breach by the Company
of any of the terms or provisions of, or constitute a default under (i) the articles of incorporation or by-laws of the Company,
each as currently in effect, (ii) any indenture, mortgage, deed of trust, or other material agreement or instrument to which the
Company is a party or by which it or any of its properties or assets are bound, including any listing agreement for the Common
Stock, except as herein set forth or an event which results in the creation of any lien, charge or encumbrance upon any assets
of the Company or the triggering of any preemptive or anti-dilution rights or rights of first refusal or first offer on the part
of holders of the Company’s securities, (iii) to its knowledge, any existing applicable law, rule, or regulation or any applicable
decree, judgment, or order of any court, United States federal or state regulatory body, administrative agency, or other governmental
body having jurisdiction over the Company or any of its properties or assets, or (iv) the Company’s listing agreement for
its Common Stock (if applicable), except such conflict, breach or default which would not have a Material Adverse Effect.

 

f.      
Approvals. No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization,
or stock exchange or market or the stockholders of the Company is required to be obtained by the Company for the entering into
and performing this Agreement and the other Transaction Documents (including without limitation the issuance and sale of the Securities
to the Buyer as contemplated by this Agreement) except such authorizations, approvals and consents that have been obtained, or
such authorizations, approvals and consents, the failure of which to obtain would not have a Material Adverse Effect.

 

g.     
SEC Filings. None of the SEC Documents contained, at the time they were filed, any untrue statement of a material fact or
omitted to state any material fact required to be stated therein or necessary to make the statements made therein in light of the
circumstances under which they were made, not misleading. The Company timely filed all requisite forms, reports and exhibits thereto
with the SEC as required. The Company is not aware of any event occurring on or prior to the execution and delivery of this Agreement
that would require the filing of, or with respect to which the Company intends to file, a Form 8-K after such time.

 

h.     
Absence of Certain Changes. Since March 31, 2014, when viewed from the perspective of the Company and its Subsidiaries taken
as a whole, there has been no material adverse change and no material adverse development in the business, properties, operations,
condition (financial or otherwise), or results of operations of the Company and its Subsidiaries (including, without limitation,
a change or development which constitutes, or with the passage of time is reasonably likely to become, a Material Adverse Effect),
except as disclosed in the SEC Documents. Since March 31, 2014, except as provided in the SEC Documents, the Company has not (i)
incurred or become subject to any material liabilities (absolute or contingent) except liabilities incurred in the ordinary course
of business consistent with past practices; (ii) discharged or satisfied any material lien or encumbrance or paid any material
obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course of business consistent
with past practices; (iii) declared or made any payment or distribution of cash or other property to stockholders with respect
to its capital stock, or purchased or redeemed, or made any agreements to purchase or redeem, any shares of its capital stock;
(iv) sold, assigned or transferred any other tangible assets, or canceled any debts or claims, except in the ordinary course of
business consistent with past practices; (v) suffered any substantial losses or waived any rights of material value, whether or
not in the ordinary course of business, or suffered the loss of any material amount of existing business; (vi) made any changes
in employee compensation, except in the ordinary course of business consistent with past practices; or (vii) experienced any material
problems with labor or management in connection with the terms and conditions of their employment.

 

    	7

    	 

    

  

i.       
Full Disclosure. There is no fact known to the Company (other than general economic conditions known to the public generally
or as disclosed in the SEC Documents) that has not been disclosed in writing to the Buyer that (i) would reasonably be expected
to have a Material Adverse Effect, (ii) would reasonably be expected to materially and adversely affect the ability of the Company
to perform its obligations pursuant to the Transaction Documents, or (iii) would reasonably be expected to materially and adversely
affect the value of the rights granted to the Buyer in the Transaction Documents.

 

j.       
Absence of Litigation. Except as described in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board or body pending or, to the knowledge of the Company, threatened against or affecting the Company,
wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect or which would adversely affect the validity
or enforceability of, or the authority or ability of the Company to perform its obligations under, any of the Transaction Documents.
The Company is not a party to or subject to the provisions of, any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality which could reasonably be expected to have a Material Adverse Effect.

 

k.     
Absence of Events of Default. No Event of Default (or its equivalent term), as defined in the respective agreement, indenture,
mortgage, deed of trust or other instrument, to which the Company is a party, and no event which, with the giving of notice or
the passage of time or both, would become an Event of Default (or its equivalent term) (as so defined in such document), has occurred
and is continuing, which would have a Material Adverse Effect.

 

l.       
No Undisclosed Liabilities or Events. The Company has no liabilities or obligations other than those disclosed in the SEC
Documents or those incurred in the ordinary course of the Company’s business since March 31, 2014, and which individually
or in the aggregate, do not or would not have a Material Adverse Effect. No event or circumstances has occurred or exists with
respect to the Company or its properties, business, condition (financial or otherwise), or results of operations, which, under
applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which
has not been so publicly announced or disclosed. There are no proposals currently under consideration or currently anticipated
to be under consideration by the Board of Directors or the executive officers of the Company which proposal would (x) change the
articles of incorporation, by-laws or any other charter document of the Company, each as currently in effect, with or without shareholder
approval, which change would reduce or otherwise adversely affect the rights and powers of the shareholders of the Common Stock
or (y) materially or substantially change the business, assets or capital of the Company.

 

    	8

    	 

    

  

m.   
No Integrated Offering. Neither the Company nor any of its affiliates nor any Person acting on its or their behalf has,
directly or indirectly, at any time during the six month period immediately prior to the date of this Agreement made any offer
or sales of any security or solicited any offers to buy any security under circumstances that would eliminate the availability
of the exemption from registration under Rule 506 of Regulation D in connection with the offer and sale of the Securities as contemplated
hereby.

 

n.     
Dilution. The number of Shares issuable upon conversion of the Debentures may increase substantially in certain circumstances,
including, but not necessarily limited to, the circumstance wherein the market price of the Common Stock declines prior to the
conversion of the Debentures. The Company’s executive officers and directors have studied and fully understand the nature
of the securities being sold hereby and recognize that they have a potential dilutive effect and further that the conversion of
the Debentures and/or sale of the Conversion Shares may have an adverse effect on the market price of the Common Stock. The Board
of Directors of the Company has concluded, in its good faith business judgment that such issuance is in the best interests of the
Company. The Company specifically acknowledges that its obligation to issue the Conversion Shares upon conversion of the Debentures
is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other
shareholders of the Company.

 

o.     
Regulatory Permits. The Company has all such permits, easements, consents, licenses, franchises and other governmental
and regulatory authorizations from all appropriate federal, state, local or other public authorities (“Permits”) as
are necessary to own and lease its properties and conduct its businesses in all material respects in the manner described in the
SEC Documents and as currently being conducted. All such Permits are in full force and effect and the Company has fulfilled and
performed all of its material obligations with respect to such Permits, and no event has occurred that allows, or after notice
or lapse of time would allow, revocation or termination thereof or will result in any other material impairment of the rights of
the holder of any such Permit, subject in each case to such qualification as may be disclosed in the Prospectus. Such Permits contain
no restrictions that would materially impair the ability of the Company to conduct businesses in the manner consistent with its
past practices. The Company has not received notice or otherwise has knowledge of any proceeding or action relating to the revocation
or modification of any such Permit.

 

p.     
Hazardous Materials. The Company is in compliance with all applicable Environmental Laws in all respects except where the
failure to comply does not have and could not reasonably be expected to have a Material Adverse Effect. For purposes of the foregoing:

 

“Environmental
Laws” means, collectively, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended,
the Superfund Amendments and Reauthorization Act of 1986, the Resource Conservation and Recovery Act, the Toxic Substances Control
Act, as amended, the Clean Air Act, as amended, the Clean Water Act, as amended, any other “Superfund” or “Superlien”
law or any other applicable federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating,
relating to, or imposing liability or standards of conduct concerning, the environment or any Hazardous Material.

 

    	9

    	 

    

  

“Hazardous Material”
means and includes any hazardous, toxic or dangerous waste, substance or material, the generation, handling, storage, disposal,
treatment or emission of which is subject to any Environmental Law.

 

q.     
Independent Public Accountants.  To the best knowledge of the Company, Rosen Seymour Shapss Martin & Company LLP is
an independent registered public accounting firm with respect to the Company, as required by the 1933 Act, the Exchange Act and
the rules and regulations promulgated thereunder.

 

r.       
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurances that (1) transactions are executed in accordance with management’s general or specific authorization; (2) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain accountability for assets; (3) access to assets is permitted only in accordance with management’s general
or specific authorization; and (4) the recorded accountability for assets is compared with existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.

 

s.Brokers. No Person (other than the Buyer
and its principals, employees and agents) is entitled to receive any consideration from the Company or the Buyer arising from any
finder’s agreement, brokerage agreement or other agreement to which the Company is a party.

 

4.      CERTAIN
COVENANTS AND ACKNOWLEDGMENTS.

 

a.      
Transfer Restrictions. The parties acknowledge and agree that (1) the Debentures have not been registered under the provisions
of the 1933 Act and, except as provided in the Registration Rights Agreement, the Shares have not been registered under the 1933
Act, and may not be transferred unless (A) subsequently registered thereunder or (B) the Securities to be sold or transferred may
be sold or transferred pursuant to an exemption from such registration; (2) any sale of the Securities made in reliance on Rule
144 promulgated under the 1933 Act (“Rule 144”) may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of such Securities under circumstances in which the seller, or the Person through whom
the sale is made, may be deemed to be an underwriter, as that term is used in the 1933 Act, may require compliance with some other
exemption under the 1933 Act or the rules and regulations of the SEC thereunder, (3) at the request of the Buyer, the Company shall,
from time to time, within two (2) business days of such request, at the sole cost and expense of the Company, either (i) deliver
to its transfer agent and registrar for the Common Stock (the “Transfer Agent”) a written letter instructing and authorizing
the Transfer Agent to process transfers of the Shares at such time as the Buyer has held the Securities for the minimum holding
period permitted under Rule 144, subject to the Buyer’s providing to the Transfer Agent certain customary representations
contemporaneously with any requested transfer, or (ii) at the Buyer’s option or if the Transfer Agent requires further confirmation
of the availability of an exemption from registration, furnish to the Buyer an opinion of the Company’s counsel in favor
of the Buyer and the Transfer Agent, reasonably satisfactory in form, scope and substance to the Buyer and the Transfer Agent,
to the effect that a contemporaneously requested transfer of shares does not require registration under the 1933 Act, pursuant
to the 1933 Act, Rule 144 or other regulations promulgated under the 1933 Act and (4) neither the Company nor any other Person
is under any obligation to register the Securities (other than pursuant to the Registration Rights Agreement) under the 1933 Act
or to comply with the terms and conditions of any exemption thereunder.

 

    	10

    	 

    

  

b.     
Restrictive Legend. The Buyer acknowledges and agrees that the Debentures, and, until such time as the Shares have been
registered under the 1933 Act as contemplated by the Registration Rights Agreement and sold in accordance with an effective Registration
Statement, certificates and other instruments representing any of the Securities shall bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of any such Securities):

 

THIS SECURITY HAS NOT BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL
BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

c.      
Registration Rights Agreement. The parties hereto agree to enter into the Registration Rights Agreement concurrently with
the execution and delivery of this Agreement.

 

d.     
Guarantee Agreement. The parties hereto agree to enter into the Guarantee Agreement concurrently with the execution and
delivery of this Agreement pursuant to which each Subsidiary of the Company shall jointly and severally guarantee the obligations
of the Company (the “Obligations”). The Guarantee Agreement executed by each Subsidiary of the Company shall terminate
following the full payment and performance of all of the Obligations hereunder and under any Transaction Document and upon Buyer’s
express written acknowledgement of such full payment and performance being received by the Company.

 

e.      
Securities Filings. The Company undertakes and agrees to make all necessary filings in connection with the sale of the Securities
to the Buyer required under any United States laws and regulations applicable to the Company (including without limitation state
“blue sky” laws), or by any domestic securities exchange or trading market, and to provide a copy thereof to the Buyer
promptly after such filing.

 

    	11

    	 

    

  

f.      
Reporting Status; Public Trading Market; DTC Eligibility. So long as the Buyer beneficially owns any Securities and any
Shares are outstanding, (i) the Company shall timely file, prior to or on the date when due, all reports that would be required
to be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act if the Company had securities registered under Section
12(b) or 12(g) of the Exchange Act; (ii) the Company shall not be operated as, or report, to the SEC or any other Person, that
the Company is a “shell company” or indicate to the contrary to the SEC or any other Person; and (iii) the Company
shall take all other action under its control necessary to ensure the availability of Rule 144 under the 1933 Act for the sale
of Shares by the Buyer at the earliest possible date. Except as otherwise set forth in Transaction Documents, the Company shall
take all action under its control necessary to obtain and to continue the listing and trading of its Common Stock (including, without
limitation, all Registrable Securities) on the OTC Markets, Inc. (“OTCM”) at the mid-tier (“OTCQB”) or
top-tier (“OTCQX”), and will comply in all material respects with the Company’s reporting, filing and other obligations
under the by-laws or rules of the National Association of Securities Dealers, Inc. (“NASD”). If, so long as the Buyer
beneficially owns any of the Securities, the Company receives any written notice from the OTCM, FINRA, NASD or the SEC with respect
to either any alleged deficiency in the Company’s compliance with applicable rules and regulations (including without limitation
any comments from the SEC on any of the Company’s documents filed (or the failure to have made any such filing) under the
1933 Act or the Exchange Act) (each, a “Regulatory Notice”), then the Company shall promptly, and in any event within
two business days, provide copies of the Regulatory Notice to the Buyer, and shall promptly, and in any event within five (5) business
days of receipt of the Regulatory Notice (a “Regulatory Response”), respond in writing to the OTCM, FIRNA,NASD and/or
SEC (as the case may be), setting forth the Company’s explanation and/or response to the issues raised in the Regulatory
Notice, with a view towards maintaining and/or regaining full compliance with the applicable rules and regulations of the OTCM,
FIRNA, NASD and/or SEC and maintaining or regaining good standing of the Company with the OTCM, FINRA, NASD and/or SEC, as the
case may be, the intent being to ensure that the Company maintain its reporting company status with the SEC and that its Common
Stock be and remain available for trading on the OTCQB or OTCQX (for the avoidance of doubt, excluding the bottom-tier OTC Pink
(or, “pink sheets”). Further, at all times when any portion of the Debentures are outstanding, the Common Stock shall
be eligible for clearing through the Depository Trust Company (“DTC”) via the DTC’s “DWAC” system,
and the Common Stock shall not be subject to any DTC “chill” designation or similar restriction on the clearing of
the Common Stock through DTC.

 

g.     
Use of Proceeds. The Company will use the proceeds from the sale of the Signing Debenture and Second Debenture (excluding
amounts paid by the Company for commitment and legal fees in connection with the sale of the Debentures) for audit and legal fees
and the sale of the Third Debenture for working capital purposes. Absent the prior written approval of a majority of the principal
amount of the Debentures then outstanding, the Company shall not use any portion of the proceeds of the sale of the Debentures
to (i) repay any indebtedness or other obligation of the Company incurred prior to the date of this Agreement outside the normal
course of business, (ii) pay any dividends or redemption amount on any of the Company’s equity or equity equivalents or (iii)
pay deferred compensation or any compensation to any of the directors or officers of the Company in excess of the rate or amount
paid or accrued during the fiscal year ended December 31, 2013, other than modest increases consistent with prior practice that
are approved by the Company’s Board of Directors.

 

    	12

    	 

    

  

h.     
Available Shares. Commencing on the date of execution and delivery of this Agreement, the Company shall have and maintain
authorized and reserved for issuance, free from preemptive rights, that number of shares equal to three hundred percent (300%)
of the number of shares of Common Stock (1) issuable based upon the Conversion Price of the then-outstanding Debentures (including
accrued interest thereon) as may be required to satisfy the conversion rights of the Buyer pursuant to the terms and conditions
of the Debenture and (2) issuable to the Buyer on future Closing Dates, based upon the lowest closing bid price per share of the
Common Stock on the date before the most recent Closing Date (as reported by Bloomberg LP). The Company shall monitor its compliance
with the foregoing requirements on an ongoing basis. If at any time the Company does not have available an amount of authorized
and non-issued Shares required to be reserved pursuant to this Section, then the Company shall, without notice or demand by the
Buyer, call within thirty (30) days of such occurrence and hold within sixty (60) days of such occurrence a special meeting of
shareholders, for the sole purpose of increasing the number of shares authorized. Management of the Company shall recommend to
shareholders to vote in favor of increasing the number of Common Stock authorized at the meeting. Members of the Company’s
management shall also vote all of their own shares in favor of increasing the number of Common Stock authorized at the meeting.
If the increase in authorized shares is approved by the stockholders at the meeting, the Company shall implement the increase in
authorized shares within one (1) business day following approval at such meeting within ten (10) business days following approval
at such meeting. Alternatively, to the extent permitted by applicable law, in lieu of calling and holding a meeting as described
above, the Company may, within thirty (30) days of the date when the Company does not have available an amount of authorized and
non-issued Shares required to be reserved as described above, procure the written consent of stockholders to increase the number
of shares authorized, and provide the stockholders with notice thereof as may be required under applicable law (including without
limitation Section 14(c) of the Exchange Act and Regulation 14C thereunder). Upon obtaining stockholder approval as aforesaid,
the Company shall cause the appropriate increase in its authorized shares of Common Stock within one (1) business day (or as soon
thereafter as permitted by applicable law).

 

i.       
Reimbursement. If (i) Buyer becomes a party defendant in any capacity in any action or proceeding brought by any stockholder
of the Company, in connection with or as a result of the consummation of the transactions contemplated by the Transaction Documents,
or if the Buyer is impleaded in any such action, proceeding or investigation by any Person, or (ii) the Buyer, other than by reason
of its gross negligence, willful misconduct or breach of law, becomes a party defendant in any capacity in any action or proceeding
brought by the SEC against or involving the Company or in connection with or as a result of the consummation of the transactions
contemplated by the Transaction Documents, or if the Buyer is impleaded in any such action, proceeding or investigation by any
Person, then in any such case, the Company will reimburse the Buyer for its reasonable legal and other expenses (including the
cost of any investigation and `preparation) incurred in connection therewith. The reimbursement obligations of the Company under
this paragraph shall be in addition to any liability which the Company may otherwise have, shall extend upon the same terms and
conditions to any affiliates of the Buyer who are actually named in such action, proceeding or investigation, and partners, directors,
agents, employees and controlling Persons (if any), as the case may be, of the Buyer and any such Affiliate, and shall be binding
upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, the Buyer and any
such Affiliate and any such Person. Except as otherwise set forth in the Transaction Documents, the Company also agrees that neither
any Buyer nor any such Affiliate, partners, directors, agents, employees or controlling Persons shall have any liability to the
Company or any Person asserting claims on behalf of or in right of the Company in connection with or as a result of the consummation
of the Transaction Documents except to the extent that any losses, claims, damages, liabilities or expenses incurred by the Company
result from the gross negligence or willful misconduct of the Buyer or from a breach of the representations, covenants and conditions
contained herein or from a breach of law.

 

    	13

    	 

    

  

j.       
 No New Indebtedness or Liens. So long as any of the Debentures remain outstanding, the Company shall not, absent the prior
written consent of the Buyer and (if any person other than the Buyer then holds any portion of the Debenture), the holders of all
Debentures then outstanding, enter into, create, incur, assume or suffer to exist any indebtedness or liens of any kind, on or
with respect to any of its property or assets now owned or hereafter acquired or any interest therein or any income or profits
therefrom that is senior to the Company’s obligations under the Debentures, other than purchase money security interests
granted to suppliers to the Company and any of the foregoing that are made in the ordinary course of business of the Company and
its Subsidiaries.

 

k.     
No Payments to Affiliates or Related Parties. So long as any of the Debentures remain outstanding if the Debentures are
in default, the Company shall not, absent the prior written consent of the holders of all Debentures then outstanding, make any
payments to any of the Company’s or the Subsidiaries’ respective affiliates or related parties, including without limitation
payments or prepayments of principal or interest accrued on any indebtedness or obligation in favor of affiliates or related parties.

 

l.       
Notice of Material Adverse Effect. The Company shall notify the Buyer (and any subsequent holder of the Debentures), as
soon as practicable and in no event later than five (5) business days of the Company’s knowledge of any Material Adverse
Effect on the Company. For purposes of the foregoing, “knowledge” means the earlier of the Company’s actual knowledge
or the Company’s constructive knowledge upon due inquiry.

 

m.   
Public Disclosure. Except to the extent required by applicable law, absent the Buyer’s prior written consent, the
Company shall not reference the name of the Buyer in any press release, securities disclosure, business plan, marketing or funding
proposal.

 

    	14

    	 

    

  

5.      TRANSFER
AGENT INSTRUCTIONS.

 

a.      
Transfer Agent Instruction Letter. The Company shall at all times while any Debentures are outstanding engage a Transfer
Agent. As of the date of this Agreement, the Transfer Agent is VStock Transfer, LLC. On or before the Signing Closing Date and
each subsequent Closing Date, the Company will irrevocably instruct its Transfer Agent in writing using the letter substantially
in the form of Exhibit D annexed hereto, executed by the Company, the Buyer, and the Transfer Agent on each Closing Date
(the “Transfer Agent Instruction Letter”), to (i) reserve that number of shares of Common Stock as is required under
Section 4(h) hereof, and (ii) issue Common Stock from time to time upon conversion of the Debentures in such amounts as specified
from time to time by the Company to the Transfer Agent, bearing the restrictive legend specified in Section 4(b) of this Agreement
prior to registration of the Shares under the 1933 Act, registered in the name of the Buyer or its permitted assigns and in such
denominations to be specified by the Buyer in connection with each conversion of the Debentures. The Transfer Agent shall not be
restricted from issuing shares from only the allotment reserved for the Conversion Amount (as defined in the Debentures), but instead
may, to the extent necessary to satisfy the amount of shares issuable upon conversion, issue shares above and beyond the amount
reserved on account of the Conversion Amount, without any additional instructions or authorization from the Company, and the Company
shall not provide the Transfer Agent with any instructions or documentation contrary to the foregoing. The Company shall continuously
monitor its compliance with the share reservation requirements and, if and to the extent necessary to increase the number of reserved
shares to remain and be at least three hundred percent (300%) of the Conversion Amount to account for any decrease in the market
price of the Common Stock, the Company shall immediately (and in any event within two (2) business days) notify the Transfer Agent
in writing of the reservation of such additional shares, provided that in the event that the number of shares reserved for
conversion of the Debentures is less than three hundred percent (300%) of the Conversion Amount, the Buyer may also directly instruct
the Transfer Agent to increase the reserved shares as necessary to satisfy the minimum reserved share requirement, and the Transfer
Agent shall act accordingly, provided, further, that the Company shall within two (2) business days provide any written
confirmation, assent or documentation thereof as the Transfer Agent may request to act upon a share increase instruction delivered
by the Buyer. The Company shall provide the Buyer with a copy of all written instructions to the Company’s Transfer Agent
with respect to the reservation of shares simultaneously with the issuance of such instructions to the Transfer Agent. The Company
covenants that no instruction other than such instructions referred to in this Section 5 and stop transfer instructions to give
effect to Section 4(a) hereof prior to registration and sale of the Converted Shares under the 1933 Act will be given by the Company
to the Transfer Agent and that the Converted Shares shall otherwise be freely transferable on the books and records of the Company
as and to the extent provided in this Agreement, the Registration Rights Agreement, and applicable law. If the Buyer provides the
Company and/or the Transfer Agent with an opinion of counsel reasonably satisfactory to the Company that registration of a resale
by the Buyer of any of the Securities in accordance with clause (1)(B) of Section 4(a) of this Agreement is not required under
the 1933 Act, the Company shall (except as provided in clause (2) of Section 4(a) of this Agreement) permit the de-legending or
transfer of the Securities and, in the case of the Converted Shares, instruct the Company’s Transfer Agent to issue one or
more certificates for Common Stock without legend in such name and in such denominations as specified by the Buyer.

 

b.     
Conversion. (i)The Company will permit the Buyer to exercise the right to convert the Debentures by telecopying, emailing
or otherwise delivering an executed and completed Notice of Conversion to the Company and/or the Transfer Agent. If so requested
by the Buyer, the Company will within one (1) business day respond with its endorsement so as to confirm the outstanding principal
amount of any Debenture submitted for conversion or shall reconcile any difference with the Buyer promptly after receiving such
Notice of Conversion.

 

    	15

    	 

    

  

(ii)              
The term “Conversion Date” means, with respect to any conversion elected by the holder of the Debentures, the date
specified in the Notice of Conversion, provided the copy of the Notice of Conversion is given either via mail or facsimile to or
otherwise delivered to the Transfer Agent and/or the Company in accordance with the provisions hereof so that it is received by
the Transfer Agent and/or the Company on or before such specified date.

 

(iii)            
The Company will transmit (or will cause the Transfer Agent to transmit) the certificates representing the Converted Shares issuable
upon conversion of any Debentures (together, unless otherwise instructed by the Buyer, with Debentures not being so converted)
to the Buyer at the address specified in the Notice of Conversion (which may be the Buyer’s address for notices as contemplated
by Section 10 hereof or a different address) via express courier, by electronic transfer or otherwise, within two (2) business
days (the “Delivery Date”) after (A) the business day on which the Company has received the Notice of Conversion (by
facsimile or other delivery) or (B) the date on which payment of interest and principal on the Debentures, which the Company has
elected to pay by the issuance of Common Stock, as contemplated by the Debentures, was due, as the case may be.

 

c.      
Failure to Timely Issue Conversion Shares. From and after the date on which the Shares have been registered under the 1933
Act as contemplated by the Registration Rights Agreement, the failure to issue unrestricted, freely tradable Conversion Shares
to the Buyer upon Conversion shall be considered a non-curable Event of Default, which, accordingly, shall entitle the Buyer(s)
whose Debentures are being converted to demand that the Debentures held by the Buyer(s) be immediately redeemed
in full by a cash payment equal to one hundred forty percent (140%) of the aggregate of the unpaid principal amount of and accrued
interest on such Debentures (whether or not the terms of such Debentures expressly permit the redemption thereof). 
The Company acknowledges that its failure to honor a Notice of Conversion shall cause definable financial hardship on the Buyer(s).

 

d.     
Duties of Company; Authorization. The Company shall inform the Transfer Agent of the reservation of shares contemplated
by Section 4(h) and this Section 5, and shall keep current in its payment obligations to the Transfer Agent such that the Transfer
Agent will continue to process share transfers and the initial issuance of shares of Common Stock upon the conversion of Debentures.
The Company hereby authorizes the Transfer Agent to correspond and otherwise communicate with the Buyer or their representatives
in connection with the foregoing and other matters related to the Common Stock. Further, the Company hereby authorizes the Buyer
or its representative to provide instructions to the Transfer Agent that are consistent with the foregoing and instructs the Transfer
Agent to honor any such instructions. Should the Company fail for any reason to keep current in its payment obligations to the
Transfer Agent, the Buyer may pay such amounts as are necessary to compensate the Transfer Agent for performing its duties with
respect to share reservation and/or de-legending certificates representing Restricted Stock, and all amounts so paid shall be promptly
reimbursed by the Company. If not so reimbursed within thirty (30) days, such amounts shall, at the option of the Buyer and without
prior notice to or consent of the Company, be added to the principal amount due under the Debenture(s) held by the Buyer, whereupon
interest will begin to accrue on such amounts at the rate specified in the Debentures.

 

    	16

    	 

    

  

e.      
Effect of Bankruptcy. The Buyer shall be entitled to exercise its conversion privilege with respect to the Debentures notwithstanding
the commencement of any case under 11 U.S.C. §101 et seq. (the “Bankruptcy Code”). In the event the Company
is a debtor under the Bankruptcy Code, the Company hereby waives, to the fullest extent permitted, any rights to relief it may
have under 11 U.S.C. §362 in respect of the Buyer’s conversion privilege. The Company hereby waives, to the fullest
extent permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of the conversion of the Debentures. The
Company agrees, without cost or expense to the Buyer, to take or to consent to any and all action necessary to effectuate relief
under 11 U.S.C. §362.  

 

6.      CLOSINGS.

 

a.      
Signing Closing. Promptly upon the execution and delivery of this Agreement, the Registration Rights Agreement, the Signing
Debenture, and all conditions in Sections 7 and 8 herein are met (the “Signing Closing Date”), (A) the Company shall
deliver to the Buyer the following: (i) the Signing Debenture; (ii) the Company Legal Opinion; (iii) the Transfer Agent Instruction
Letter; (iv) duly executed counterparts of the Transaction Documents; (v) an officer’s certificate of the Company confirming
the accuracy of the Company’s representations and warranties contained herein; and (vi) fees and shares of Common Stock due
under Section 12 of this Agreement; and (B) the Buyer shall deliver to the Company the following: (i) $112,500 (the “Signing
Purchase Price”) and (ii) duly executed counterparts of the Transaction Documents (as applicable).

 

b.     
Second Closing. Approximately sixty one (61) days following the Signing Closing Date, subject to the mutual agreement of
the Buyer and the Company, for the “Second Closing Date” and subject to satisfaction of the conditions set forth in
Sections 7 and 8, (A) the Company shall deliver to the Buyer the following: (i) the Second Debenture; (ii) the Company Legal Opinion
dated as of the Second Closing Date, provided that a Company Legal Opinion need not be delivered at the Second Closing Date if
the Company has previously delivered to the Buyer a “blanket” legal opinion covering the Debentures to be issued at
the Second Closing Date and the Company has not been notified by its counsel that such opinion has been withdrawn or modified;
(iii) an amendment to the Transfer Agent Instruction Letter instructing the Transfer Agent to reserve that number of shares of
Common Stock as is required under Section 4(h) hereof, if necessary; and (iv) an officer’s certificate of the Company confirming,
as of the Second Closing Date, the accuracy of the Company’s representations and warranties contained herein and updating
Schedule 3.1 to reflect the Company’s capitalization as of the Second Closing Date; and (B) the Buyer shall deliver
to the Company the following: $112,500 (the “Second Purchase Price”).

 

c.      
Third Closing. Approximately sixty one (61) days following the Second Closing Date, on a date determined upon mutual agreement
of the Buyer and the Company for the “Third Closing Date” and subject to satisfaction of the conditions set forth in
Sections 7 and 8, (A) the Company shall deliver to the Buyer the following: (i) the Third Debenture; (ii) the Company Legal Opinion
dated as of the Third Closing Date, provided that a Company Legal Opinion need not be delivered at the Third Closing Date if the
Company has previously delivered to the Buyer a “blanket” legal opinion covering the Debentures to be issued at the
Third Closing Date and the Company has not been notified by its counsel that such opinion has been withdrawn or modified; (iii)
an amendment to the Transfer Agent Instruction Letter instructing the Transfer Agent to reserve that number of shares of Common
Stock as is required under Section 4(h) hereof, if necessary; and (iv) an officer’s certificate of the Company confirming,
as of the Third Closing Date, the accuracy of the Company’s representations and warranties contained herein and updating
Schedule 3.1 to reflect the Company’s capitalization as of the Third Closing Date; and (B) the Buyer shall deliver
to the Company the following: $112,500 (the “Third Purchase Price”).

 

    	17

    	 

    

  

d.     
Location and Time of Closings. Each Closing shall be deemed to occur on the related Closing Date at the office of the Buyer’s
counsel and shall take place no later than 5:00 P.M., New York time, on such day or such other time as is mutually agreed upon
by the Company and the Buyer.

 

7.      CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.

 

The Company’s
obligation to sell the Debentures to the Buyer pursuant to this Agreement on each Closing Date is conditioned upon:

 

a.      
Purchase Price. Delivery to the Company of good funds as payment in full of the Purchase Price for the Debentures at each
Closing in accordance with this Agreement;

 

b.     
Representations and Warranties; Covenants.  The accuracy on the Closing Date of the representations and warranties of the
Buyer contained in this Agreement, each as if made on such date, and the performance by the Buyer on or before such date of all
covenants and agreements of the Buyer required to be performed on or before such date; and

 

c.      
Laws and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or restricting
the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained.

 

8.      CONDITIONS
TO THE BUYER’S OBLIGATION TO PURCHASE.

 

The Buyer’s obligation
to purchase the Debentures at the Closing is conditioned upon:

 

a.      
Transaction Documents. The execution and delivery of this Agreement, the Guarantee Agreement and the Registration Rights
Agreement by the Company;

 

b.     
Debenture(s). Delivery by the Company to the Buyer of the Debentures to be purchased in accordance with this Agreement;

 

c.      
S-1 Registration Statement. The acceptance by the Buyer, in its sole but reasonable discretion, of a draft copy of an amendment
no. 2 to the Form S-1 Registration Statement (Registration No. 333-193769), to be filed with the SEC, which includes the Investor
as a “Selling Shareholder”, and seeks to register on behalf of the Investor, three hundred percent (300%) of the amount
of the Registrable Securities (as defined in the Registration Rights Agreement) as additional securities to be registered thereunder.
The number of shares to be registered shall be calculated using a price for each share of Common Stock equal to sixty five percent
(65%) of the lowest closing bid price (as reported by Bloomberg LP) of Common Stock for the twenty (20) trading days immediately
preceding the date of the Company’s amendment to the S-1 Registration Statement.

 

    	18

    	 

    

   

d.     
Opinion of Counsel. Delivery by the Company to the Buyer of an opinion of counsel to the Company, substantially in the form
attached hereto as Exhibit E and dated as of the Closing Date (the “Company Legal Opinion”) or if such Company
Legal Opinion is a “blanket” opinion covering the Debentures to be issued on such Closing Date, a prior date;

 

e.      
Representations and Warranties; Covenants. The accuracy in all material respects on the Closing Date of the representations
and warranties of the Company contained in this Agreement, each as if made on such date, and the performance by the Company on
or before such date of all covenants and agreements of the Company required to be performed on or before such date;

 

f.      
Corporate Resolutions. Delivery by the Company to the Buyer a copy of resolutions of the Company’s board of directors,
approving and authorizing the execution, delivery and performance of the Transaction Documents and the transactions contemplated
thereby in the form attached hereto as Exhibit F;

 

g.     
Officer’s Certificate. Delivery by the Company to the Buyer of a certificate of the Chief Executive Officer of the
Company in the form attached hereto as Exhibit G;

 

h.     
Search Results. Copies of UCC search reports, issued by the Secretary of State of the state of incorporation of the Company,
dated such a date as is reasonably acceptable to Buyer, listing all effective financing statements which name the Company, under
its present name and any previous names, as debtors, together with copies of such financing statements;

 

i.       
Certificate of Good Standing. Copy of a certificate of good standing with respect to the Company, issued by the Secretary
of State of the state of incorporation of the Company, dated such a date as is reasonably acceptable to Buyer, evidencing the good
standing thereof;

 

j.       
Laws and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or restricting
the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained; and

 

k.     
Adverse Changes. From and after the date hereof to and including the Closing Date, (i) the trading of the Common Stock shall
not have been suspended by the SEC, FINRA, or the NASD and trading in securities generally on OTCM shall not have been suspended
or limited, nor shall minimum prices been established for securities traded on the OTCM; (ii) there shall not have occurred any
outbreak or escalation of hostilities involving the United States or any material adverse change in any financial market that in
either case in the reasonable judgment of the Buyer makes it impracticable or inadvisable to purchase the Debentures.

 

    	19

    	 

    

  

9.      GOVERNING
LAW; MISCELLANEOUS. 

 

a.      
MANDATORY FORUM SELECTION. Any dispute arising under, relating to, or in connection
with the Agreement or related to any matter which is the subject of or incidental to the Agreement (whether or not such claim is
based upon breach of contract or tort) shall be subject to the exclusive jurisdiction and venue of the state and/or federal courts
located in MIAMI-DADE County, Florida.  This provision is intended to be a “mandatory” forum selection clause
and governed by and interpreted consistentLY with Florida law.

 

b.     
Governing Law. Except in the case of the Mandatory Forum Selection clause above, this Agreement shall be delivered and accepted
in and shall be deemed to be contracts made under and governed by the internal laws of the State of Nevada, and for all purposes
shall be construed in accordance with the laws of the State of Nevada, without giving effect to the choice of law provisions. To
the extent determined by the applicable court described above, the Company shall reimburse the Buyer for any reasonable legal fees
and disbursements incurred by the Buyer in enforcement of or protection of any of its rights under any of the Transaction Documents.

 

c.      
Waivers. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in
exercising such right or remedy, shall not operate as a waiver thereof.

 

d.     
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each
of the parties hereto.

 

e.      
Construction. All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as
the context may require.

 

f.      
Facsimiles; E-mails. A facsimile or email transmission of this signed Agreement or a Notice of Conversion under the Debentures
shall be legal and binding on all parties hereto. Facsimile signatures shall be the equivalent of original signatures.

 

g.     
Counterparts. This Agreement may be signed in one or more counterparts, each of which shall be deemed an original.

 

h.     
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

    	20

    	 

    

  

i.       
Enforceability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability
of this Agreement in any other jurisdiction.

 

j.       
Amendment. This Agreement may be amended only by the written consent of a majority in interest of the holders of the Debentures
and an instrument in writing signed by the Company.

 

k.     
Entire Agreement. This Agreement supersedes all prior agreements and understandings among the parties hereto with respect
to the subject matter hereof.

 

l.       
No Strict Construction. This Agreement shall be construed as if both Parties had equal say in its drafting, and thus shall
not be construed against the drafter.

 

m.   
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

10.  NOTICES. 

 

Any notice required
or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given on the
earliest of:

 

a.      
the date delivered, if delivered by personal delivery as against written receipt therefor or by confirmed facsimile transmission,

 

b.     
the seventh business day after deposit, postage prepaid, in the United States Postal Service by registered or certified mail, or

 

c.      
the third business day after mailing by next-day express courier, with delivery costs and fees prepaid, in each case, addressed
to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate
by ten (10) days’ advance written notice similarly given to each of the other parties hereto):

 

	COMPANY:    	
        Surepure, Inc.

        405 Lexington Avenue, 25th Floor

        New York, NY 10174

        Attention: Stephen M. Robinson

        Email: Stephen.robinson@surepureinc.com

         

        With copies to (which shall not constitute
        notice):

         

        Barton LLP

        420 Lexington Avenue, 18th Floor

        New York, NY 10170

        Attention: William A. Newman, Esq.

        Email: wnewman@bartonesq.com

 

    	21

    	 

    

 

	 	 
	 	 
	BUYER:	
        Peak One Opportunity Fund, L.P.

        333 South Hibiscus Drive

        Miami Beach, FL 33139

        Attention: Jason Goldstein

        Email: jgoldstein@peakoneinvestments.com

         

	 	
        With copies to (which shall not constitute
        notice):

         

	 	
        Lucosky Brookman LLP

        101 Wood Avenue South, 5th Floor

        Woodbridge, NY 08830

        Attention: Seth Brookman, Esq.

        Email: sbrookman@lucbro.com

         

        and

         

        Zabatta Group, LLP

        91 Central Park West, Suite 1H

        New York, NY 10023

        Attention: Patrick G. Zabatta, Esq.

        Email: pzabatta@peakoneinvestments.com

 

11.  SURVIVAL
OF REPRESENTATIONS AND WARRANTIES. The Company’s representations and warranties herein shall survive for so long as any
Debentures are outstanding, and shall inure to the benefit of the Buyer, its successors and assigns.

 

12.  FEES;
EXPENSES.

 

a.      
Commitment Fee. The Company shall pay to Peak One Investments, LLC a non-accountable fee (the “Commitment Fee”)
of $5,000 and 75,000 shares of Restricted Stock to cover the expenses and analysis performed in connection with the analysis of
the Company and the propriety of the Buyer’s making the contemplated investment.

 

b.     
Legal Fees. The Company will pay the legal fees of the Buyer’s counsel (the “Legal Fees”) in the amount
of $5,000. The Company further agrees to pay in full the reasonable legal fees of the Buyer’s counsel incurred after the
Signing Closing Date incurred in connection with the Transaction Documents (including enforcement of the Company’s obligations
or the exercise of the Buyer’s remedies thereunder).

 

c.      
Payment of Fees and Expenses. The Company will pay the Commitment Fee, Legal Fees and issue the required number of shares
of Restricted Stock on the Signing Closing Date. In furtherance of the foregoing, in that connection, the Company hereby authorizes
the Buyer to deduct such amounts from the Purchase Price and transmit same to the respective payee. Notwithstanding the foregoing,
if for any reason any such Closings do not occur, then the Company shall remain liable to pay the Commitment Fee and Legal Fees
as provided in Sections 12(a) and (b) and shall remit payment to the Buyer within five (5) days after the Buyer delivers to the
Company a notice and demand for payment thereof. The Company shall pay disbursements of the Buyer’s legal counsel and legal
fees incurred after the Signing Closing Date within ten (10) days of invoice therefor.

 

[Signature Page Follows]

 

    	22

    	 

    

 

IN WITNESS WHEREOF, this Agreement
has been duly executed by the Buyer and the Company as of the date first set forth above.

 

	 	COMPANY: 

	 	 	 
	 	SUREPURE, INC. 

	 	 	 
	 	By: 	/s/ Stephen Robinson
	 	
        Name:

        
	Stephen Robinson
	 	Title:	CFO
	 	 	 
	 	 	 
	 	BUYER: 

 

	 	PEAK ONE OPPORTUNITY FUND, L.P.

	 	
        

        

        

        
	 
	 	By: 	Peak One Investments, LLC,
	 	 	its General Partner
	 	 	 
	 	By:	/s/ Jason Goldstein
	 	Name: Jason Goldstein
	 	Title: Managing Member

 

 

 

[Signature Page to Securities Purchase Agreement]

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]